Ligand Pharmaceuticals LGND Development and Licensing of Biopharmaceutical Assets — Stock-Based Comp
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — stock-based comp?
- Ligand Pharmaceuticals (LGND) reported development and licensing of biopharmaceutical assets — stock-based comp of $10.6M in Q1 2026.
- How has Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — stock-based comp changed year-over-year?
- Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — stock-based comp increased by 35.2% year-over-year, from $7.84M to $10.6M.
- What is the long-term trend for Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — stock-based comp?
- Over 3 years (2022 to 2025), Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — stock-based comp has grown at a -8.1% compound annual growth rate (CAGR), from $60.29M to $46.85M.
- What does development and licensing of biopharmaceutical assets — stock-based comp mean?
- This metric measures the non-cash expense recognized for equity-based awards granted to employees and service providers within the development and licensing segment. It reflects the cost of aligning human capital incentives with long-term shareholder value creation. Monitoring this expense is essential for understanding the true economic cost of talent acquisition and retention within the segment.